NCT04659382
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04659382 |
| Title | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (SIRTCI) |
| Acronym | SIRTCI |
| Recruitment | Unknown status |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Federation Francophone de Cancerologie Digestive |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | FRA |
CKB BOOST